AGCO Invests EUR 70 million in AGCO Power Facility in Linnavuori, Finland to Increase Sustainable Product Offerings and Support Future Growth
21.3.2024 08:45:00 EET | Business Wire | Press release
AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology, is announcing a EUR 70 million investment in its Linnavuori plant in Nokia, Finland to accelerate further clean energy innovations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320982805/en/
The picture shows AGCO Power's Linnavuori factory area. New investments are marked in the picture. Photo by: AGCO Power. Photo is in free use.
The extensive investment will allow the building of a clean energy laboratory to test fuel cells for alternative fuels and select electric drives that will reduce farmers’ fleet emissions. Improvements also include a training and visitor centre, a production hall for machining cylinder heads and manufacturing components for automated Continuously Variable Transmissions (CVTs), a paint shop and testing capabilities for remanufactured engines. The new buildings totalling 11,000 square metres and will be completed throughout 2024 and 2025.
“We are investing in the future of clean energy, Linnavuori and, ultimately, AGCO. By adding production capacity and research capabilities, AGCO Power is building capabilities to better serve our workforce and all farmers who are sustainably feeding the world,” said Juha Tervala, Managing Director of AGCO Power.
The AGCO Power Linnavuori plant employs about 1,000 employees; these investments lay the foundation for future growth. The latest additions illustrate a history of growth in Finland. In November 2023, the President of the Republic of Finland Sauli Niinistö recognized both AGCO Power and one of AGCO’s leading brands, Valtra, operating from Suolahti, with a long-term investment award. AGCO’s investments in the AGCO Power Linnavuori plant operations have totalled more than EUR 100 million over the past five years.
Testing new technology
In addition to diesel engines, AGCO is expanding its product technology portfolio by developing engines utilising alternative fuels and various electrical solutions that reduce emissions. The new research laboratory in Linnavuori is a natural extension of AGCO Power’s product development responsibility.
“The clean energy laboratory will house several cells for testing the combustion engines running on alternative fuels, as well as a range of electric solutions, such as hybrids, fuel cells and high-voltage battery technology,” said Mr. Tervala.
Circular economy since 1990
AGCO Power products are built to last, and even after years of heavy use, their value and life can still be extended through remanufacturing. Restoring engines to a like-new state goes well beyond repair; remanufactured products are stripped down to their individual components, inspected, cleaned and fully rebuilt. The improvements in reman testing capabilities in Linnavuori are part of AGCO’s global investments in remanufacturing.
“We have remanufactured used engines toward a circular economy since 1990. The product improvements are based on the latest revision, and the repaired, tested and painted engine is granted a full factory warranty. The investments in our Linnavuori plant will allow us to grow our reman capabilities to serve global customers,” continued Mr. Tervala.
Growth in machining volumes
AGCO is centralising its transmission components’ manufacturing operations in Linnavuori to maximize the facility’s history of quality and expertise. The investments will now allow the facility to expand the manufacturing of CVT components for AGCO’s leading brand tractors with plans to produce more high precision transmission components in this location.
“Currently, we produce approximately one million gear wheels and axles annually, but this number is expected to double after the investments,” said Mr. Tervala.
The new production hall will also house a new machining line with a high degree of automation for manufacturing the cylinder heads of AGCO Power CORE engines.
About AGCO Power
AGCO Power in Linnavuori, Nokia, is one of the world’s leading manufacturers of diesel engines. Together with its production plants operating in China, Brazil and Argentina, AGCO Power designs and manufactures engines used as the power sources of many of the world’s leading tractor brands including Fendt, Valtra and Massey Ferguson. AGCO Power, which has been in operation for more than 80 years, is part of the AGCO.
About AGCO
AGCO (NYSE: AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers customer value through its differentiated brand portfolio including core brands like Fendt®, GSI®, Massey Ferguson®, Precision Planting® and Valtra®. Powered by Fuse® smart farming solutions, AGCO’s full line of equipment and services helps farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $14.4 billion in 2023. For more information, visit www.AGCOcorp.com. For company news, information, and events, please follow us on X: @AGCOCorp. For financial news on X, please follow the hashtag #AGCOIR.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320982805/en/
Contact information
Communications Manager Vilja Pylsy
Vilja.Pylsy@AGCOcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
